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(30–90%) to all oral antibiotics. CONCLUSIONS: TMP-
SMX should no longer be recommended for empiric 
treatment of this disease and should be replaced by nitro-
furantoin. The decrease in resistance to amoxycillin +
clavulanic acid observed for E. coli shows that interven-
tions designed to improve antibiotic prescribing may play
a valuable role in the global effort to combat antibiotic
resistance. Furthermore, the data presented illustrates
that longitudinal surveillance of antibiotic resistance
should be an integral component in the formulation of
antibacterial pharmacopolicy.
INFECTION—Cost Studies
PIN8
PROSPECTIVE STUDY ON ACUTE LOWER
RESPIRATORY TRACT INFECTIONS IN 
GERMAN CHILDREN YOUNGER THAN 3 YEARS
(PRI.DE)—ECONOMIC IMPACT OF
HOSPITALIZED CASES
Ehlken B1, Berger K1, Ihorst G2, Petersen G3, Forster J4
1MERG—Medical Economics Research Group, Munich,
Germany; 2Institute of Medical Statistics, University Freiburg,
Freiburg, Germany; 3Wyeth, Münster, Germany; 4St.
Josefskrankenhaus and University Children’s Hospital Freiburg,
Freiburg, Germany
OBJECTIVES: To calculate the average cost per hospi-
talized patient (case) with lower respiratory tract infec-
tion (LRTI) and to estimate the economic impact of LRTI
due to RSV, parainﬂuenza and inﬂuenza viruses in
Germany. Costs were evaluated from the perspectives of
third party payer, parents and society. METHODS: This
economic analysis is part of the PRI.DE study, which is a
prospective, multicenter, population-based epidemiologi-
cal study. It was carried out over 2 years (1999–2001) on
the impact of LRTI in children aged 0 to 36 months in
Germany. Inclusion of children with pneumonia, bron-
chitis, bronchiolitis, croup and apnea. Nasopharyngeal
secretions were tested for RSV, parainﬂuenza-(PIV), and
inﬂuenza viruses (IV) by Hexaplex PCR (Prodesse, USA).
Medical services consumed were generated by chart ion.
Data regarding parental expenses were collected via tele-
phone interviews within 4 weeks after hospitalization by
using standardized questionnaires. RESULTS: A total of
1035 evaluable cases with community-acquired infections
treated as inpatients enrolled in 6 hospitals were analysed.
Total costs per hospitalized community-acquired LRTI
case amount to €2579 (SD 1874). Main cost driver is
direct medical cost (91%). Mean hospital length of stay
is 7.4 days (SD 6.5). For children under 1 year (n = 596),
total costs amount to €2827 (SD 2213), whereas the costs
for older children (1 to 3 years; n = 439) are lower
(€2242; SD 1132). Total cost of LRTI caused by RSV (n
= 350) is €2772 (SD 1603), caused by PIV (n = 74) €2374
(SD 1644) and by IV (n = 35) €2596 (SD 1214). Treat-
ment of LRTI caused by other pathogens costs on average
€2482 (SD 2131). Annual total expenditures due to hos-
pitalized cases of community-acquired LRTI amount to
€158 million. CONCLUSIONS: LRTI in children up to
the age of three years cause a considerable economic
burden to the health care system in Germany.
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OBJECTIVE: Until 2001 serotype prevalence of
meningococcal disease in Portugal was unknown. Fol-
lowing the ﬁrst release of data it was found that a high
prevalence of type C disease existed in Portugal (>50%
all serotypes). Several conjugated vaccines are currently
available, all having several possible vaccination schemes.
This study estimates the cost-effectiveness of two differ-
ent vaccination schemes using the vaccine MeningiteC®.
METHODS: Using an Excel-based model we estimated
the impact of vaccinating 100,000 children, using alter-
natively 2 different vaccination schemes (1 vs 3 doses).
Disease prevalence was assumed as the one found during
the year previous to the introduction of the vaccine. The
vaccine was assumed as having a 92% efﬁcacy for 5 years,
with no herd immunity. Costs were obtained from ofﬁ-
cial sources, when available. The estimation of resources
for disease and sequelae treatment was obtained by con-
sulting several clinical experts. Costs were determined in
2002 Euros and a discount rate of 5% was used, as
required by Portuguese guidelines. RESULTS: For each
100.000 children vaccinated, using a 3-dose scheme will
result in 345,36 Life-Years Gained (LYG), with cost-
effectiveness ratios of €29.575/LYG—societal, and
€11.272/LYG—3rd payer, while the vaccination with
only one dose will result in 297,58 LYG, with ratios of
€10.806/LYG and €3.768/LYG, respectively. The results
found are sensitive to vaccine price, epidemiology of
disease and mortality rates. Resources consumed due to
disease and sequelae did not inﬂuence ﬁnal results 
considerably. CONCLUSION: Use of meningococcal C
vaccine in Portugal is expected to be cost-effective pro-
vided that no substantial change in the prevalence of the
disease occurs. Decision to use 1 or 3 doses will depend
on both society’s and parent’s willingness to pay since
incremental cost-effectiveness ratios for the 3 vs 1 dose
scheme are considerably high.
PIN10
A COST CONSEQUENCE ON CONCOMITANT
DRUG USE DURING HCV THERAPY IN
MANAGED CARE PATIENTS IN THE UNITED
STATES
Le TK,Yu H
TIER, Bridgewater, NJ, USA
